News

Special Sections

Athenex and MAIA Get Approval for Generic Levothyroxine for Hypothyroidism

Edward Kim | Equities.com |

Hypothyroidism affects 4.6% of the US population aged 12 and older (Image: NIH)


Stemline Gets First FDA Approval for Rare Blood Disease Therapy

Edward Kim | Equities.com |

Elzonris (tagraxofusp) is the first approved treatment for blastic plasmacytoid dendritic dell neoplasm (BPDCN) and first CD123-targeted therapy (Image: Stemline Therapeutics)


Kalytera Shows Positive Phase 2 Data with CBD in Acute Graft vs Host Disease (GvHD)

Edward Kim | Equities.com |

Interim data from first cohort shows no patients have developed severe or life-threatening GvHD (Image: Kalytera Therapeutics)


Sutro Biopharma Achieves Another Milestone in Celgene Partnership

Edward Kim | Equities.com |

Latest $10 million payment from Celgene triggered by development of spray drying technology that advances commercial-scale manufacturing (Image: Sutro Biopharma).


Erasca Announces Launch with $42 Million Series A Round Targeting Cancer

Edward Kim | Equities.com |

Co-founder Jonathan Lim, MD, was CEO of Ignyta, which was acquired by Roche in February 2018 for $1.7 billion.


Evofem Biosciences Shows Positive Top-Line Phase 3 Results for Hormone-Free Birth Control

Edward Kim | Equities.com |

Amphora showed 98.7% efficacy in preventing births when used correctly (Image: Evofem Biosciences)


BioCardia Submits FDA Application for New Steerable Cardiovascular Introducer

Edward Kim | Equities.com |

The AVANCE is designed to introduce cardiovascular catheters into the heart, including via the interatrial septum (Image: BioCardia)


Windtree Shows New Positive Phase 2b Data in Respiratory Distress Syndrome Infants

Edward Kim | Equities.com |

Data shows reduced incidence and severity of bronchopulmonary dysplasia in preterm Infants with RDS (Image: Windtree Therapeutics)


Q BioMed Partners with SRI to Develop Pediatric Developmental Nonverbal Disorder Therapy

Spotlight Companies | Equities.com |

Part of Q BioMed's autistic spectrum disorder drug development program (Image: Autism Speaks)


BioLineRx Begins Triple Combination Arm of Phase 2a Pancreatic Cancer Trial

Edward Kim | Equities.com |

BL-8040 + Keytruda + chemotherapy combination in metastatic pancreatic cancer (Image: BioLineRx)


Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     

Can the Media Solve the Partisan Conflict?

Andrew McCarthy, Contributing Editor, The National Review; Michael Zeldin, CNN Legal Analyst; Celeste Katz, Senior Political Reporter, Glamour; Silvia Davi, SVP, Contributing Editor, Equities.com; and Doug Simon, CEO, D S Simon Media discuss how the media’s role has shaped the landscape for communicators and what the media is trying to do to reduce discord in society.